A connected device is an adjunct, not the treatment itself
Pelvic floor biofeedback devices use a sensor, commonly pressure or electromyography, to turn muscle activity into a visual or audio signal. A connected version may add an app, exercise timer, reminders, progress charts or remote review. The signal can help someone understand whether a contraction was detected, but it does not by itself show that the correct muscles were used, that relaxation was complete or that a symptom has been correctly diagnosed.
Urinary leakage has different patterns and causes. Stress incontinence, urgency incontinence, mixed symptoms, difficulty emptying, pain and prolapse symptoms do not all need the same plan. NICE recommends history, examination and categorisation before treatment, and offers supervised pelvic floor muscle training for at least 3 months as first-line treatment for stress or mixed urinary incontinence [1][5]. A device bought before assessment can reinforce an ineffective technique or delay care for a different problem.
- Start with the symptom and clinical goal, not the gadget.
- Confirm that contraction and relaxation are being performed correctly.
- Treat app scores as training signals, not as a diagnosis or measure of overall pelvic health.
The overall evidence is more restrained than many claims
The 2025 Cochrane review included 41 studies and 3,483 women. For pelvic floor muscle training with biofeedback versus training alone, it found little or no difference in incontinence-related quality of life, probably little or no difference in patient-reported cure or improvement, and a small reduction of 0.29 leakage episodes per 24 hours that was unlikely to be clinically important [2]. Satisfaction may have been higher, but that evidence was low certainty. Most participants had stress urinary incontinence, and the review excluded pregnancy and the first 6 postpartum months.
A 2024 multicentre trial in 452 women with new postpartum stress urinary incontinence found a different result in that specific setting. After 3 months, cure was reported in 20.2% of the pressure-biofeedback group and 8.7% of the home-training group, while improvement was reported in 59.2% and 44.5%, respectively [3]. Both groups received supervised training. In contrast, the large OPAL trial found no important difference between electromyographic biofeedback and basic pelvic floor muscle training at 24 months [4]. Together, these results support selective use and shared decision making, not a claim that every connected device improves outcomes.
- Ask whether evidence matches the device, symptom type and life stage being considered.
- Distinguish short-term engagement from sustained symptom improvement.
- Compare the device plus good training with good training alone, not with no care.
Who may benefit from biofeedback support
NICE does not recommend routine perineometry or pelvic-floor electromyography as biofeedback for all women. It advises considering electrical stimulation and/or biofeedback when a woman cannot actively contract the pelvic floor, in order to support motivation and adherence [1]. A trained pelvic health professional may also use feedback to demonstrate technique, set an individual programme or help a person connect a verbal cue with a physical response.
The best candidate is not simply someone who wants more data. It is someone with a defined problem, a confirmed ability or difficulty, a goal that the feedback can plausibly support and a plan for review. Pain, overactivity and difficulty relaxing require particular caution because repeated strengthening is not automatically appropriate. If a person cannot feel a contraction, has persistent symptoms despite training or develops new pelvic pain, reassessment matters more than increasing a device score.
- Use baseline symptoms and function to define success.
- Agree how long to try the device and when technique will be reassessed.
- Include relaxation, breathing and symptom-specific care when clinically indicated.
Safe use depends on the sensor, the body and the context
An intravaginal or rectal sensor may cause discomfort, discharge or spotting. The Cochrane review found few adverse-event data, although reported events were generally minor and short-lived [2]. Users should follow the exact cleaning, insertion, storage and single-user instructions, stop if use causes pain or bleeding and seek clinical advice for persistent symptoms. A clinician should review suitability during pregnancy, early postpartum recovery, after pelvic surgery, during an active infection or when unexplained bleeding is present rather than assuming that a general consumer label covers every situation.
Biofeedback and electrical stimulation are not the same. A sensor may only measure activity, while a stimulator delivers current. FDA reports for electrical muscle stimulators include shocks, burns, bruising, skin irritation, pain and interference with implanted devices such as pacemakers [6]. A device that includes stimulation needs its own regulatory status, contraindications and instructions. Marketing language such as wellness, smart or connected does not remove those requirements.
- Check whether the product senses, stimulates or does both.
- Verify that it is legally marketed for the intended use in the country where it will be used.
- Do not insert a device or continue training through pain, bleeding or signs of infection without assessment.
Connected care must protect context as well as data
A pelvic-floor trace is intimate health data. FDA cybersecurity guidance for connected medical devices emphasises secure design, transparent labelling and lifecycle risk management [7]. Before syncing a device, a user should know what is collected, whether raw signals or only summaries are stored, who can see them, how long they are retained, whether they are used to train algorithms and how deletion works. Remote clinician access can support adherence, but it also creates a duty to explain whether anyone is actively monitoring the feed and how urgent concerns should be raised.
A responsible programme measures outcomes that people can feel: fewer leakage episodes, less urgency, improved participation, reduced pad use or progress toward an agreed activity. It also records discomfort, drop-out and unequal access. Device engagement is not a clinical outcome. The sleekest dashboard is useful only when it strengthens a correctly chosen, supervised plan and routes non-response back to a clinician rather than asking the user to train harder indefinitely.
- State clearly whether data are monitored live, periodically or not at all.
- Offer a non-connected option when possible.
- Review symptoms and function at a defined point, not only streaks and repetitions.
What the evidence cannot yet answer
- Trials combine different sensors, feedback formats, supervision levels and urinary-incontinence populations, so results cannot be transferred to every commercial product.
- The strongest overall synthesis found little added benefit from biofeedback, while a narrower postpartum trial found benefit in a supervised programme.
- Evidence is limited for long-term outcomes, pelvic pain, prolapse, pregnancy, early postpartum use and algorithm-generated coaching.
Questions worth taking into care
- What symptom and diagnosis is this device intended to address?
- Does it sense muscle activity, deliver electrical stimulation or do both?
- Has a trained clinician checked my contraction and relaxation technique?
- What outcome will we review after 3 months, and what happens if it does not improve?
- Who can see the connected data, and is anyone actually monitoring it?
Source record
Evidence used in this review
Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.
- [1]Urinary Incontinence and Pelvic Organ Prolapse in Women: Management
National Institute for Health and Care Excellence · 2019
- [2]
- [3]
- [4]
- [5]Quality Statement 4: Supervised Pelvic Floor Muscle Training
National Institute for Health and Care Excellence · 2021
- [6]Electronic Muscle Stimulators
U.S. Food and Drug Administration · 2018
- [7]Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
U.S. Food and Drug Administration · 2026
This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.